-
Je něco špatně v tomto záznamu ?
New HPMA copolymer-based drug carriers with covalently bound hydrophobic substituents for solid tumour targeting
P Chytil, T Etrych, C Konak, M Sirova, T Mrkvan, J Boucek, B Rihova, K Ulbrich
Jazyk angličtina Země Nizozemsko
NLK
ScienceDirect (archiv)
od 1993-01-01 do 2009-12-31
- MeSH
- doxorubicin analogy a deriváty farmakokinetika farmakologie chemie MeSH
- financování organizované MeSH
- hydrofobní a hydrofilní interakce MeSH
- kyseliny polymethakrylové farmakokinetika farmakologie chemie MeSH
- lidé MeSH
- methakryláty farmakokinetika farmakologie chemie MeSH
- myši inbrední C57BL MeSH
- myši MeSH
- nádorové buněčné linie MeSH
- nádory farmakoterapie metabolismus MeSH
- nosiče léků farmakokinetika farmakologie chemie MeSH
- proliferace buněk účinky léků MeSH
- protinádorová antibiotika farmakokinetika farmakologie chemie MeSH
- transplantace nádorů MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- myši MeSH
- zvířata MeSH
Various conjugates of anticancer drug doxorubicin (Dox) covalently bound by the hydrolytically degradable hydrazone bond to the drug carrier based on N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers were synthesised. Structure of the conjugates differed in the type and the content of hydrophobic substituent (dodecyl, oleic acid and cholesterol moieties) introduced into the polymer structure. In aqueous solutions the conjugates self-assembled into high-molecular-weight supramolecular structures, such as polymeric micelles or stable hydrophilic nanoparticles 13-37 nm in diameter, depending on the type and the content of hydrophobic substituents. Treatment of mice bearing EL-4 T cell lymphoma with the conjugates in the therapeutic regime of drug administration (i.v.) resulted in significant tumour regression with up to 100% of long-term survivors, depending on the dose and the detailed structure of the carrier. The nanoparticles formed by the conjugate bearing cholesterol moiety exhibited prolonged blood circulation and enhanced tumour accumulation indicating an important role of the EPR effect in excellent anticancer activity of the conjugate.
- 000
- 03568naa 2200601 a 4500
- 001
- bmc11003075
- 003
- CZ-PrNML
- 005
- 20121129101041.0
- 008
- 110225s2008 ne e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Chytil, Petr. $7 _AN032430
- 245 10
- $a New HPMA copolymer-based drug carriers with covalently bound hydrophobic substituents for solid tumour targeting / $c P Chytil, T Etrych, C Konak, M Sirova, T Mrkvan, J Boucek, B Rihova, K Ulbrich
- 314 __
- $a Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, v. v. i., Heyrovsky Sq. 2, 162 06 Prague 6, Czech Republic.
- 520 9_
- $a Various conjugates of anticancer drug doxorubicin (Dox) covalently bound by the hydrolytically degradable hydrazone bond to the drug carrier based on N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers were synthesised. Structure of the conjugates differed in the type and the content of hydrophobic substituent (dodecyl, oleic acid and cholesterol moieties) introduced into the polymer structure. In aqueous solutions the conjugates self-assembled into high-molecular-weight supramolecular structures, such as polymeric micelles or stable hydrophilic nanoparticles 13-37 nm in diameter, depending on the type and the content of hydrophobic substituents. Treatment of mice bearing EL-4 T cell lymphoma with the conjugates in the therapeutic regime of drug administration (i.v.) resulted in significant tumour regression with up to 100% of long-term survivors, depending on the dose and the detailed structure of the carrier. The nanoparticles formed by the conjugate bearing cholesterol moiety exhibited prolonged blood circulation and enhanced tumour accumulation indicating an important role of the EPR effect in excellent anticancer activity of the conjugate.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a protinádorová antibiotika $x farmakokinetika $x farmakologie $x chemie $7 D000903
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a proliferace buněk $x účinky léků $7 D049109
- 650 _2
- $a doxorubicin $x analogy a deriváty $x farmakokinetika $x farmakologie $x chemie $7 D004317
- 650 _2
- $a nosiče léků $x farmakokinetika $x farmakologie $x chemie $7 D004337
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hydrofobní a hydrofilní interakce $7 D057927
- 650 _2
- $a methakryláty $x farmakokinetika $x farmakologie $x chemie $7 D008689
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a myši inbrední C57BL $7 D008810
- 650 _2
- $a transplantace nádorů $7 D009368
- 650 _2
- $a nádory $x farmakoterapie $x metabolismus $7 D009369
- 650 _2
- $a kyseliny polymethakrylové $x farmakokinetika $x farmakologie $x chemie $7 D011109
- 650 _2
- $a financování organizované $7 D005381
- 700 1_
- $a Etrych, Tomáš $7 xx0068504
- 700 1_
- $a Koňák, Čestmír. $7 _AN026017
- 700 1_
- $a Šírová, Milada $7 xx0127158
- 700 1_
- $a Mrkvan, Tomáš $7 xx0062385
- 700 1_
- $a Bouček, Jan. $7 _AN059867
- 700 1_
- $a Říhová, Blanka, $d 1942- $7 jo20000073671
- 700 1_
- $a Ulbrich, Karel, $d 1947- $7 jo2004259877
- 773 0_
- $t Journal of Controlled Release $w MED00002621 $g Roč. 127, č. 2 (2008), s. 121-130
- 910 __
- $a ABA008 $b x $y 1
- 990 __
- $a 20110413114340 $b ABA008
- 991 __
- $a 20121129101109 $b ABA008
- 999 __
- $a ok $b bmc $g 830464 $s 695067
- BAS __
- $a 3
- BMC __
- $a 2008 $b 127 $c 2 $d 121-130 $m Journal of controlled release $n J Controlled Release $x MED00002621
- LZP __
- $a 2011-2B/dkme